Press Releases

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (NASDAQ:INSM) today announced that Eugene Sullivan, M.D. has joined Insmed as its Chief Medical and Scientific Officer. Dr. Sullivan will report to Will Lewis, President and Chief Executive Officer. Several highlights from Dr. Sullivan's career include:

• Former pulmonary physician at the Cleveland Clinic
• Former Deputy Director at US Food and Drug Administration
• Former Chief Medical Officer of United Therapeutics

Dr. Sullivan joins Insmed with more than 20 years of experience with a focus on pulmonary and orphan diseases. He is a medical doctor trained in internal medicine, pulmonary medicine and critical care medicine and practiced at the Cleveland Clinic from 1995 to 1999. From 1999 through 2006, Dr. Sullivan held several positions at the U.S. Food and Drug Administration, including Deputy Director of the Division of Pulmonary and Allergy Products. From 2007 through 2012, Dr. Sullivan was the Chief Medical Officer of United Therapeutics. In recent years, Dr. Sullivan was a Vice President, Global Regulatory Affairs at Astra Zeneca and consulted to companies, including Insmed, on clinical drug development and strategic regulatory matters.

"I am extremely pleased to welcome Gene to the Insmed team. His broad clinical and regulatory experience with both development stage and commercial products will be very valuable to Insmed. Gene is actively involved as an author, lecturer and advisor on medical and regulatory matters affecting orphan drugs and pulmonary diseases. His experience will provide new insight and valuable perspective as we advance ARIKAYCE, INS1009 and our other pipeline candidates while building Insmed into a leading biopharmaceutical company," said Mr. Lewis.

"It is a pleasure to join Will and the Insmed team. The Company's focus on developing and acquiring therapeutics for unmet medical needs in pulmonary and orphan diseases offers a very exciting professional opportunity. Throughout my career I have been keenly focused on delivering benefit to patients in these underserved therapeutic indications. I look forward to being a part of this dynamic leadership team as we bring new treatments to patients suffering from these serious lung diseases," commented Dr. Sullivan.

Dr. Sullivan graduated summa cum laude from the University of Maryland with a Bachelor of Science degree. He earned his medical degree from the University of Maryland, School of Medicine and conducted his internship and residency in Internal Medicine at the Medical College of Virginia. Dr. Sullivan completed his fellowship training in Pulmonary and Critical Care Medicine at the University of Colorado Health Sciences Center and received a Masters of Pulmonary Vascular Disease from the University of Bologna in Italy.

About Insmed

Insmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious lung diseases. Insmed is focused on the development and commercialization of ARIKAYCE™, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the Company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. For more information, please visit http://www.insmed.com.

Forward-looking statements

This release contains forward-looking statements. Words, and variations of words, such as "intend," "expect," "will," "anticipate," "believe," "continue," "propose" and similar expressions are intended to identify forward-looking statements. Investors are cautioned that such statements in this release, including statements relating to the status, results and timing of clinical trials and clinical data, the anticipated benefits of Insmed's products, the anticipated timing of regulatory submissions, and the ability to obtain required regulatory approvals, bring products to market and successfully commercialize products constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, without limitation, failure or delay of European, Canadian, U.S. Food and Drug Administration and other regulatory reviews and approvals, competitive developments affecting the Company's product candidates, delays in product development or clinical trials or other studies, patent disputes and other intellectual property developments relating to the Company's product candidates, unexpected regulatory actions, delays or requests, the failure of clinical trials or other studies or results of clinical trials or other studies that do not meet expectations, the fact that subsequent analyses of clinical trial or study data may lead to different (including less favorable) interpretations of trial or study results or may identify important implications of a trial or study that are not reflected in Company's prior disclosures, and the fact that trial or study results or subsequent analyses may be subject to differing interpretations by regulatory agencies, the inability to successfully develop the Company's product candidates or receive necessary regulatory approvals, the inability to make product candidates commercially successful, changes in anticipated expenses, changes in the Company's financing requirements or ability to raise additional capital, and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2014. Investors are cautioned not to place undue reliance on any forward-looking statements that speak only as of the date of this news release. The Company undertakes no obligation to update these forward-looking statements to reflect events or circumstances or changes in its expectations.

Investor Relations:
LHA
Anne Marie Fields, 212-838-3777
Senior Vice President
afields@lhai.com
or
Bruce Voss, 310-691-7100
Managing Director
bvoss@lhai.com